a b s t r a c t N-arachidonoyl dopamine (NADA) is an endogenous ligand that activates the cannabinoid type 1 receptor and the transient receptor potential vanilloid type 1 channel. Two potential biosynthetic pathways for NADA have been proposed, though no conclusive evidence exists for either. The first is the direct conjugation of arachidonic acid with dopamine and the other is via metabolism of a putative Narachidonoyl tyrosine (NA-tyrosine). In the present study we investigated these biosynthetic mechanisms and report that NADA synthesis requires TH in dopaminergic terminals; however, NAtyrosine, which we identify here as an endogenous lipid, is not an intermediate. We show that NADA biosynthesis primarily occurs through an enzyme-mediated conjugation of arachidonic acid with dopamine. While this conjugation likely involves a complex of enzymes, our data suggest a direct involvement of fatty acid amide hydrolase in NADA biosynthesis either as a rate-limiting enzyme that liberates arachidonic acid from AEA, or as a conjugation enzyme, or both.
Introduction
N-arachidonoyl dopamine (NADA) was recently identified as an endogenous capsaicin-like compound that displays nanomolar potency for cannabinoid type 1 receptors (CB 1 ) and transient receptor potential vanilloid type 1 (TRPV1) channels. It is found in brain areas with a high density of TRPV1 (i.e., the striatum, hippocampus, cerebellum, and dorsal root ganglia (DRG)) [1] [2] [3] , suggesting it may be an endogenous ligand for this channel.
In DRG neurons, NADA increased intracellular Ca 2+ through activation of CB 1 receptors and depolarized membrane potential via TRPV1 channels [1, 4] . NADA also increased TRPV1-mediated release of substance P and calcitonin gene-related peptide (CGRP) in rat dorsal spinal cord slices [1] . Furthermore, NADA enhanced TRPV1-mediated paired-pulse depression by increasing GABAergic transmission in rat hippocampal slices [1] . NADA also initiated vasorelaxant effects via the activation of TRPV1 and CB 1 receptors in small mesenteric vessels [5] . Finally, NADA leads to a CB 1 -mediated reduction of GABAergic and glutamatergic transmission, and to TRPV1-mediated stimulation of glutamatergic transmission, onto dopaminergic neurons in rat substantia nigra slices [6] .
In addition to the in vitro effects described above, NADA exerts opposing effects on pain modulation via the activation of CB 1 and TRPV1, respectively. In contrast to CB 1 -mediated analgesia observed when administrated intraperitoneally (i.p.) in mice (10 mg/kg), NADA induced TRPV1-mediated thermal hyperalgesia (EC 50 ¼ 1.5 mg/50 ml ¼ 68.2 mM) when injected intradermally (i.pl.) into the rat hindpaw [1, 3] . Correspondingly, Huang and Walker [7] identified the neural correlates of behavioral thermal hyperalgesia in anesthetized rats. They found that when administrated intradermally (i.pl.) into the receptive fields of dorsal horn nociceptive neurons of the ipsilateral hindpaw, NADA increased both spontaneous and heat-evoked activity in spinal nociceptive neurons. NADA-induced neural hypersensitivity was dosedependent (EC 50 ¼ 1.55 mg/50 ml ¼ 68.2 mM) and TRPV1-dependent, but CB 1 -independent. However, other researchers found that NADA inhibited both CB 1 -mediated innocuous mechanically evoked responses of dorsal horn neurons and TRPV1-mediated noxious-evoked responses of dorsal horn neurons, when injected intradermally (i.pl.) into the receptive fields of neurons [4] . These findings suggest complex effects of NADA on sensory neurons, presumably due to the differential expression of CB 1 receptors and TRPV1 channels on the primary afferent fibers and/or different molecular mechanisms for different stimulus modalities [4] .
As a putative endocannabinoid and endovanilloid, NADA may play a role in pain and inflammation through the activation of CB 1 and TRPV1. Therefore, it is important to elucidate the pathways of its biosynthesis. There are several potential routes for NADA biosynthesis, based on previous knowledge of the formation of dopamine or of the occurrence of phospholipid aminolysis. One possibility is that NADA may be synthesized from a putative NA-tyrosine that could be converted to NA-L-DOPA and NADA by the same enzymes that convert tyrosine to dopamine; another possible mechanism is through the conjugation of arachidonic acid with dopamine (see Fig. 1 ). Huang et al. [1] observed that a compound with chromatographic properties identical to NADA could be biosynthesized in rat brain homogenates incubated with radiolabeled arachidonic acid and dopamine or tyrosine. In addition, the enzymatic formation of the radiolabeled NADA-like compound from tyrosine was reduced by inhibition of TH, which is evidence in support of both this and the aforementioned route [1] . In either of the above cases, the conjugation of dopamine or tyrosine and arachidonic acid might occur via direct condensation or via the previous formation of arachidonoyl-CoA, which would be more reactive to the nucleophilic attack by the NH 2 group of the two amines. Finally, NADA might be formed in principle also via the dopamine-induced aminolysis of the arachidonoyl-glycerol ester bond in phospholipids [8] , or else its synthesis might use as biosynthetic precursor a preferential pool of arachidonic acid esterified in phospholipids rather than free or CoA-activated arachidonic acid. NADA is rapidly taken up by a putative endocannabinoid transporter in C6 glioma cells and is hydrolyzed (albeit significantly more slowly than AEA) by fatty acid amide hydrolase (FAAH) to arachidonic acid and dopamine [1] . Conversely, NADA was shown to be a good substrate for O-catecholaminemethyltransferase in this experiment [1] . To date it is not known whether manipulation of FAAH activity affects NADA levels. Recently FAAH was reported to participate in the synthesis of N-arachidonoyl phenolamine (AM404) by conjugation of arachidonic acid to exogenously administered acetaminophen [9] and, therefore, a potential participant in an arachidonic acid and dopamine conjugation pathway.
The aim of this study was to examine these proposed biosynthetic pathways for NADA using both in vivo and in vitro assays and to investigate the involvement of several enzymes, including FAAH in regulating NADA production. We demonstrate that NA-tyrosine is formed endogenously in rat brain; however, it does not appear to be a precursor for NADA in the striatum. Additionally, in vitro experiments suggest that arachidonoyl CoA and arachidonic acid esterified to phospholipids are not direct precursors to NADA. However, we do show through both in vitro and in vivo assays that the primary biosynthetic pathway is via conjugation of arachidonic acid to dopamine through a FAAHdependent pathway. FAAH is likely acting as part of a complex of Fig. 1 . Two potential pathways for NADA biosynthesis. Pathway A involves the conjugation of dopamine with arachidonic acid (AA). Pathway B involves NA-tyrosine, hypothesized to be metabolized sequentially by TH and AADC to form NA-DOPA and NADA, respectively. mitochondrial enzymes that are involved in the biosynthesis and metabolism of the larger family of N-acyl amides.
Materials and methods

Animals
Male Sprague-Dawley rats (Charles River, Boston, MA) weighing between 300 and 400 g served as experimental subjects. All animals were housed in groups prior to surgery, and singly thereafter, under controlled lighting conditions (lights on from 7 AM to 7 PM) and at room temperature. Food and water were available ad libitum. Additionally, 10 mice were used. Five wildtype and five FAAH knockout mice used in this study were littermates from the thirteenth generation offspring from intercrosses of 129SvJ-C57BL/6 FAAH (7) mice [10] . All protocols were approved by the Brown University, Indiana University, and Scripps Research Institutional Animal Care and Use Committee.
Chemicals
All 
Partial purification of dopamine and NADA in rat brain
Striata were homogenized in 2 ml of ice-cold methanol by sonication with a Brinkmann sonicator (Kinematica GmbH, Switzerland) for 1 min and centrifuged at 31,000g at 4 1C for 20 min. Supernatants were removed and 2 ml of 1 M Tris buffer solution containing 0.1% glutathione and 0.1% semicarbazide hydrochloride (adjusted to pH 8.5 with 1 M HCl) was added to methanol extract. Silica-based 500 mg phenylboronic acid solidphase cartridges (PBA, Varian, Harbor City, CA) were conditioned with 1 ml methanol, 1 ml water, and 1 ml saturated NaHCO 3 buffer solution (pH 9). The extract was loaded on PBA cartridges and passed through by gentle low-pressure aspiration. After washing with 1 ml water and 2 ml methanol, dopamine was eluted from cartridges with 0.5, 1, and 1 ml of 5 M formic acid/methanol (1:5, v/v). 1 ml of each elution was then used for LC/MS/MS analysis. Dopamine was chromatographed by an isocratic method with a mobile phase containing 5% methanol, 0.05% acetic acid, and 1 mM ammonium acetate. After the LC/MS/MS analysis for dopamine, 2.7 ml water was added to the original 2.5 ml eluent. C18-SD (4 mm/1 ml) high-performance extraction disk cartridges (3 M Bioanalytical Technologies, St. Paul, MN) were conditioned with 150 ml methanol and 300 ml water. The samples were loaded on the disk cartridges (1 ml) and washed with 300 ml 5% methanol. NADA was eluted with 100 ml methanol and 10 ml of each elution was used for LC/MS/MS analysis. NADA was chromatographed by gradient elution: mobile phase A: 20% methanol, 0.5% acetic acid, 1 mM ammonium acetate; mobile phase B: 100% methanol, 0.5% acetic acid, 1 mM ammonium acetate; 25% B to 100% B 5.50 min, followed by 1 min re-equilibration with 25% B.
Analysis of all extracts was performed with an Applied Biosystems/MDS Sciex (Foster City, CA) API 3000 triple quadrupole mass spectrometer (LC/MS/MS). Dopamine samples were injected onto a 100-mm Aquasil C18 reversed phase HPLC column (2.1-mm internal diameter, 0.200 ml/min) (Thermo Electron Corporation, San Jose, CA) and NADA samples were injected onto a 50-mm Zorbax Eclipse XDB-C18 reversed phase HPLC column (2.1-mm internal diameter, 0.200 ml/min) (Agilent Technologies Inc., New Castle, DE). Levels were analyzed in multiple reaction monitoring mode (MRM) on the LC/MS/MS system. In MRM mode, detection is based on the fragmentation of the precursor ion (MH 
Partial purification of NA-tyrosine in rat brain
Using six fresh male rat brains, lipid extractions were performed as previously described [1, 10] . Levels of NA-tyrosine were analyzed in MRM mode on the LC/MS/MS system with a method optimized with the synthetic standard that generated a parent ion of NA-tyrosine, MH À ¼ m/z 466.3 and product ions ¼ m/z 118.9, 162.9, and 179.9. The gradient used to elute NA-tyrosine was the same as that used for NADA. NA-tyrosine standards were added to separate brain extracts to obtain percentage recoveries.
Nano-HPLC quadrupole TOF analysis for NA-tyrosine
Exact mass measurements and structural characteristics of NAtyrosine from rat brain extracts were made with a quadrupole time-of-flight (qTOF) LC/MS/MS mass spectrometer as previously described [13] . One difference in the methodologies was that the ESI voltage was À3000 V to generate a negatively charged NAtyrosine molecular ion, whereas the previous report identified N-palmitoyl glycine with a positive voltage. The mobile phase used to elute L-DOPA was the same as that used for dopamine, and the gradient used to elute NA-L-DOPA was the same as that used for NADA. Percentage recoveries for L-DOPA and NA-L-DOPA samples were determined by separate assay solutions processed in the presence of L-DOPA and NA-L-DOPA standards.
6-Hydroxydopamine (6-OHDA) lesions
Rats (n ¼ 5) were initially injected with desipramine (15 mg/ kg, i.p.) to protect noradrenergic terminals. Under deep nembutal anesthesia (45 mg/kg, i.p.) rats received a unilateral 6-OHDA lesion (total 8 mg in 4 ml of 0.008% ascorbic acid kept on ice) to the left medial forebrain bundle over an 8-min period (coordinates from bregma: anteroposterior, À3.0 mm; mediolateral, À1.4 mm; dorsoventral, À9.5 mm from skull). The syringe was left in place for 1 min before removal. Seven days after surgery, both left (lesioned side) and right (control side) striata were removed from 6-OHDA lesioned animals and were processed for LC/MS/MS analysis as described above for analysis of dopamine and NADA.
TH inhibition
Rats (n ¼ 4 at each time point) were injected intraperitoneally the TH inhibitor, DL-a-methyltyrosine methyl ester HCl (AMPT) (115 mg/kg) [14] and sacrificed at 90, 180, 270, 360, and 450 min. Both the ipsilateral and contralateral striata were quickly dissected and frozen on dry ice (stored thereafter at À80 1C for no more than 2 weeks). Control animals were sacrificed immediately (time ¼ 0) after injection of distilled water (vehicle). The striata were processed as described above for analysis of dopamine and NADA. In addition, rat brains (n ¼ 8) obtained at 270 min after AMPT injection were processed according to the NAtyrosine extraction procedure for LC/MS/MS analysis.
NA-tyrosine (1 mM) was incubated separately with 16.5 mg TH at 37 1C for 10 min in 100 ml of 50 mM PIPES, pH 6.0, which also includes 1 mM BH 4 , 50 mg/ml catalase, and 5 mM DTT. The reaction was terminated with 300 ml 100% methanol (final volume 400 ml). Buffer or boiled enzyme conditions were also tested. After termination of the reaction, the NA-L-DOPA assay solution (400 ml) was used for LC/MS/MS analysis as promote recovery from sedation. One hour after surgery, both left (experimental side) and right (control side) striata were removed and processed according to the NADA extraction procedure for further LC/MS/MS analysis as described above. membrane, and non-incubated conditions were also tested. Following incubation, the preparation was extracted and analyzed by the procedure for NADA described above. Rat second pellet (P 2 ) brain membranes were prepared as described by Huang et al. [15] .
Experiments with arachidonoyl-CoA in homogenates
For these experiments rat striatal, midbrain, or hippocampal slices were homogenized in Tris-HCl buffer (50 mM, pH 7. [6] . The lower limit of detection for NADA using this method was 0.5 pmol and was sufficient in previous studies to detect NADA following high potassium stimulation of midbrain slices [6] .
Experiments with radiolabeled arachidonic acid incorporated into the plasma membrane
Confluent rat C6 glioma cells were incubated overnight with [5,6,8,9,11,12,14,15- 2.14. Effects of FAAH inhibition on striatal levels of AEA and NADA Animals were injected with either URB597 (0.3 mg/kg, in 1% DMSO, i.p.) or vehicle. After 2 h animals were decapitated and striata were dissected and flash-frozen in liquid nitrogen, extracted, purified, and analyzed as described above.
Analysis of striatal extracts from FAAH knockout and wild-type mice
FAAH knockout and wild-type mice were sacrificed when they were 6 weeks old. The striata were dissected and stored at À80 1C until used. Lipid extraction, partial purification, and quantitation were performed with methods identical to those described above.
Recombinant FAAH cell-free assay
To determine the rates of hydrolysis a solution of ethanol and compound (400 mM, 10 ml) was added to a solution of recombinant FAAH protein (10 ml, 1.3 mg/ml in 20 mM HEPES (pH 7.8), 150 mM NaCl, 10% glycerol, 1% Triton X-100) in buffer (Tris/EDTA, 380 ml, pH 9) at room temperature. A 40 ml aliquot of the reaction mixture was taken at appropriate time points and quenched with 1 ml of MeOH. To control for loss of AEA and NADA to the sides of the tube and into micelles in the aqueous buffer, equal numbers of controls were run at the same time without FAAH. One microliter of the quenched solution from each (FAAH incubations and controls) was analyzed by LC/MS/MS mass spectrometry as discussed above. Hydrolysis rates were determined by the average values of the analyte measured from the FAAH incubations subtracted from the average values of the controls at each time point.
Data analysis
The quantitation of analytes was made via the Analyst software (Applied Biosystems-MDS Sciex; Framingham MA) quantitation wizard that quantifies the amount of analyte in femtomoles (fmol) per injection in an unknown sample based on the regression fit of known values from synthetic standards. Each of these comparisons was statistically analyzed using SPSS software (Chicago, IL). Statistical differences were determined using one-way analysis of variance (ANOVA). The effects of 6-OHDA on the striatal NADA levels were analyzed by nonparametric Wilcoxon signed-ranks tests because the NADA levels on the lesioned side dropped below our detection limit (o1 fmol). The time-dependent effects of AMPT injection on striatal dopamine and NADA levels were first analyzed by one-way ANOVA and then the levels of striatal dopamine and NADA at each time point were compared with those of controls (time ¼ 0 min), respectively, by using Dunnett post-hoc comparison. Data are presented as mean7SE of the means where po0.05 was considered statistically significant.
Results
NADA biosynthesis in striatum requires dopaminergic terminals and TH
NADA is most abundant in the striatum, which is the brain region with the greatest dopamine content; therefore we examined whether striatal NADA levels are dopamine-dependent.
6-OHDA (8 mg/4 ml) was injected into the left medial forebrain bundle to damage dopaminergic terminals and observed an 85% decrease in dopamine in the lesioned striatum ( Fig. 2A) . Correspondingly, the levels of NADA in the lesioned striatum fell below our detection limit (o1 fmol) (Fig. 2B) . This result suggested that NADA biosynthesis in the striatum requires dopaminergic terminals. However, because 6-OHDA lesions also deplete striatal TH, we next examined the role of TH, the ratelimiting enzyme in dopamine synthesis, in NADA biosynthesis.
To test whether NADA biosynthesis requires TH, rats were injected with the TH inhibitor AMPT (115 mg/kg, i.p.), and striata were subsequently removed at 90, 180, 270, 360, and 450 min intervals. The control animals were injected with vehicle (distilled water) and immediately sacrificed. LC/MS/MS analysis revealed a time-dependent decrease in striatal levels of both dopamine, which fell to 44% of control and NADA, which fell to 27% of control, 360 min after AMPT injection supporting the involvement of TH in NADA biosynthesis (Fig. 3A and B) .
Identification of endogenous NA-tyrosine in rat brain
N-arachidonoyl-tyrosine (NA-tyrosine) is a potential NADA precursor; therefore, we examined the possibility that it is produced in the brain. Identification of NA-tyrosine (Fig. 4A ) was accomplished using a partially purified brain lipid extract that was analyzed by nano-LC-quadrupole/time-of-flight mass spectrometry (nano-HPLC/QqTOF MS) and by chromatographic matching using LC/MS/MS. Nano-HPLC/QqTOF MS isolated a lipid compound within the brain extract with an exact mass of 466.3058, which is within 20 parts per million of the expected mass of NA-tyrosine (466.3038; Table 1 ). Additionally, the fragmentation pattern of the 466.3058 mass was the same as that produced by the synthetic standard (Fig. 4B) , which is considered a mass fingerprint. Likewise, with LC/MS/MS using a technique that filters for the parent ion (466 amu) and pairs it with a predicted fragment (180 amu) a chromatographic match was revealed of a compound in the brain extract that matched with the NA-tyrosine standard (Fig. 4C) . Taken together, these 
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The levels of NADA in the lesioned striata fell below our detection limit (o1 fmol) (mean NADA level on lesioned sideo1 fmol/g striatum vs. mean NADA level on untreated side ¼ 1894 fmol/g striatum, *po0.05, nonparametric Wilcoxon signed-ranks tests).
data support the hypothesis that NA-tyrosine is produced in the brain.
Examination of NA-tyrosine as a precursor of striatal NADA
With the evidence that NA-tyrosine is present in the brain, we examined the possibility that NADA biosynthesis occurs via metabolism of NA-tyrosine to NA-L-DOPA by TH, which would then be metabolized to NADA by L-amino acid decarboxylase (AADC) (Fig. 1) . NADA levels were significantly decreased 270 min after the TH inhibitor AMPT injection (Fig. 3B) ; therefore, we examined whether NA-tyrosine accumulated after TH inhibition. However, no significant increase was found, suggesting that NA-tyrosine may not be a substrate for TH in vivo. In order to substantiate this interpretation, we tested whether TH could convert NA-tyrosine to NA-L-DOPA in vitro. We incubated L-tyrosine ( striata, which implied that NA-L-DOPA is not converted to NADA in the striatum. Together, these data indicated that it is unlikely that NADA biosynthesis occurs via metabolism of NA-tyrosine or NA-L-DOPA.
No detectable NADA is formed via arachidonoyl-CoA and dopamine incubation with brain membranes
It is likely that NADA is formed via conjugation of arachidonoyl-CoA and dopamine. However, when homogenates of striatal, midbrain, or hippocampal rat slices were incubated with 50 mM of NADA (retention time 17 min) was observed with any of the conditions tested. Although the measurement of radioactivity in chromatographic fractions was previously shown to be sensitive enough to detect the enzymatic formation of radiolabeled NADA [1] , we decided to also analyze the HPLC fraction at 16-18 min retention time by either positive or negative ion LC-APCI-MS. No peak at the m/z expected from NADA or its loss was found. When the experiment was repeated in the presence of either 1 mM Ca 2+ or 50 mM thimerosal, to stimulate potential calcium-sensitive enzymes or to reduce arachidonoyl-CoA incorporation into phospholipids and triacylglycerols and diacylglycerol, similar negative results were obtained. Finally, when ascorbic acid was included in the reaction to inhibit dopamine oxidation, still no NADA-like material was found. results were obtained when whole-cell homogenates from radiolabeled C6 cells were incubated at 37 1C for increasing periods of time (0-60 min) with 100 mM dopamine.
NADA biosynthesis occurs via conjugation of arachidonic acid with dopamine in rat brain membranes
Previously, the hypothesis that NADA could be formed by conjugation of arachidonic acid with dopamine was examined using radiolabeled precursors and TLC characterization of the enzymatic products [9] . In the current study, the possibility that NADA biosynthesis occurs through conjugation of arachidonic acid with dopamine was investigated quantitatively by incubating rat brain membranes with 20, 50, and 100 mM [ concentration-dependent with higher concentrations of precursors, leading to higher concentrations of product (Fig. 5 ). An enzymatic mechanism is likely as deuterated NADA was not detected when the substrates were incubated with buffer alone or with boiled membranes (Fig. 5) . These results indicate that NADA can be synthesized through the enzymatic conjugation of arachidonic acid and dopamine via an enzymatic process.
Endogenous level of striatal NADA after URB597 injections in rats and in FAAH knockout and wild-type mice
To determine whether FAAH modulates endogenous NADA levels, we examined AEA and NADA levels in rats treated with URB597 or vehicle and in FAAH knockout and wild-type mice. The levels of AEA in rat striatum significantly increased 2 h after systemic injection of the FAAH inhibitor URB597 (0.3 mg/kg) compared to vehicle controls (Fig. 6A) . In contrast, striatal levels of NADA significantly decreased (Fig. 6A) . The same pattern was observed in the striatal levels of AEA and NADA in FAAH knockout and wild-type mice: AEA levels were significantly higher, whereas NADA levels were significantly lower in striata from FAAH knockout mice (Fig. 6B) . 
NADA is a poor substrate for recombinant FAAH
The evidence that NADA levels were significantly decreased with FAAH inhibition and in FAAH knockout mice led us to test the hypothesis that (1) FAAH is acting as a biosynthetic enzyme with AEA and dopamine as precursors and (2) NADA is a poor substrate for FAAH. If NADA is a high-affinity substrate for FAAH producing robust levels of hydrolysis, then it is unlikely to play a role in its biosynthesis. Conversely, if AEA were converted to NADA during hydrolysis in the presence of dopamine, then FAAH would in fact be a candidate enzyme for NADA biosynthesis. Our results show that when recombinant FAAH was incubated with AEA and dopamine, AEA was measured via HPLC/MS/MS and was shown to be rapidly hydrolyzed as expected (Fig. 7A) . At 3 min $80% of all AEA was hydrolyzed and by $10 min over 95%. At 30 min there was almost no detectable AEA present in the solution. Conversely, at 3 min less than 10% of NADA was hydrolyzed and at 30 min there was still over 50% of NADA still left in the solution. Surprisingly, trace amounts of NADA were produced in a timedependent manner when AEA and dopamine were incubated with FAAH. Small amounts of NADA were detected throughout the incubation during the first 15 min and at 30 min, when there was no detectable AEA (therefore, an abundance of liberated arachidonic acid), and up to $3% of NADA production was measured (mole for mole compared to a theoretical 100% AEA). To control for any carry-over or MS contamination of NADA, which has a history of carry-over on columns and in tubing (unpublished observations), we used new columns and tubing and performed the recombinant FAAH incubations with deuterium-labeled NADA ([H 8 ] NADA; Fig. 7A) . Therefore, the NADA that was measured via HPLC/MS/MS after incubation of AEA and dopamine with recombinant FAAH could not be carry-over contaminants. 
Discussion
In the present study we investigated several biosynthetic mechanisms for NADA and report that NADA synthesis requires TH in dopaminergic terminals and occurs through an enzymemediated conjugation of arachidonic acid with dopamine and not through the endogenous NA-tyrosine. One enzyme involved in the biosynthetic process is fatty acid amide hydrolase, the blockade of which significantly decreases in vivo the production of NADA.
Lesion studies of the striatum supported the hypothesis that NADA is synthesized in dopaminergic terminals where TH is located. One potential implication of the significant decrease in NADA production measured after striatal lesions is that K m of the conjugation reaction for dopamine is high, so that small decreases in dopamine concentration may lead to large decreases in NADA. However, this has not been examined in vitro.
We originally proposed two potential pathways for NADA biosynthesis: one mediated by metabolism of the putative precursor NA-tyrosine and the other via direct conjugation of arachidonic acid with dopamine [1] . However, based on the lesion studies presented here, it is hard to distinguish which of these two pathways is dominant in NADA biosynthesis since the essential molecular component for both pathways, TH, was depleted under conditions of dopaminergic terminal destruction or TH inhibition. To elucidate the primary pathway in NADA biosynthesis, we determined that NA-tyrosine is a naturally occurring molecule in the rat, a conclusion based on mass spectrometric analysis (LC/MS/MS and nano-HPLC/QqTOF), showing that the exact masses, column retention times, and fragmentation patterns of the constituent found in rat brain were virtually identical to those of NA-tyrosine. Although our results support the existence of endogenous NA-tyrosine, which could be a precursor for NADA biosynthesis via TH, our data did not support the hypothesis that NA-tyrosine is a precursor for NADA biosynthesis given the following: (1) NA-tyrosine did not accumulate after TH inhibition, (2) incubating deuterium-labeled NA-tyrosine with purified recombinant TH failed to produce deuterated NA-L-DOPA, and (3) the injection of deuterium-labeled NA-L-DOPA into striatum failed to produce deuterated NADA. These results suggest that NA-tyrosine is a poor substrate for TH in vivo and in vitro and that the presence of NA-tyrosine in rat brain might have little to do with NADA biosynthesis. Rather, it is possible that endogenous NA-tyrosine is an endogenous signaling molecule with a separate function to NADA and/or a mediator for biosynthesis of other N-arachidonoyl amino acids, such as the previously identified conjugates of arachidonic acid with glycine, alanine, g-aminobutyric acid, and serine [15, 16] . However, it is important to keep in mind that the possibility of NA-tyrosine conversion into NA-L-DOPA by enzymes other than TH in vivo cannot be ruled out by the above results. It is also possible, though unlikely, that the failed production of NADA from NA-L-DOPA injection may due to compartmentalization. A faster degradation of exogenous NA-L-DOPA than its uptake into cells and then conversion into NADA may also explain the negative findings in the current study.
Confirmed here is the hypothesis that NADA is synthesized via conjugation of arachidonic acid and dopamine through an enzyme-dependent process. Whether or not intermediates are formed as part of this process remains uncertain. Although little is known about the enzyme(s) involved in NADA biosynthesis, Huang et al. [1] proposed a possible mechanism similar to the formation of N-arachidonoyl glycine (NAGly) [10] . The enzyme, arachidonoyl-CoA synthetase, which belongs to an enzymatic family of acyl-CoA synthetase, converts arachidonic acid into arachidonoyl-CoA in the brain, platelets, and aorta [17] [18] [19] . A second family of enzymes, the acyl-coenzyme A:glycine N-acyltransferases, may conjugate glycine to various aliphatic and aromatic acyl-CoAs [20] [21] [22] [23] [24] [25] . Here, we tested the possible role of arachidonoyl-CoA in the direct formation of NADA and were unable to produce NADA under several experimental conditions. Likewise, we did not observe the formation of any NADA-like HPLC component from arachidonic acid incorporated into phospholipids when using either intact cell or cell-free conditions. It is possible that the bioavailability of these intermediates is an issue and that the biosynthetic process is such that there is a ratelimiting step that initiates the production of NADA and in the absence of this step NADA would not be formed even with an excess of substrate.
A recent report showed that FAAH can participate in the in vivo synthesis of AM404 by conjugation of arachidonic acid to exogenously administered acetaminophen [9] . We examined whether striatal levels of NADA were changed after pharmacological or genetic inhibition of FAAH. That the normal NADA levels in rat striatum could be so dramatically decreased with FAAH inhibition and also that FAAH knockout mice have significantly less NADA than wide-type mice were convincing evidence that FAAH was in some way involved in the biosynthesis of NADA. Accordingly, FAAH mRNA is moderately expressed in striatum and FAAH activity is detectable in rat striatum [26] . Also, an increased level of striatal AEA and a decreased activity of FAAH were observed after destruction of dopaminergic terminals by 6-OHDA [27] . These data support the possibility that FAAH has the potential to be involved in the direct conjugation of dopamine with arachidonic acid liberated from AEA, and is the rate-limiting enzyme for NADA biosynthesis. Alternately, the decreased levels of striatal NADA by FAAH inhibition or depletion may result from elevation of AEA concentrations in the striatum. Maccarrone et al. [28] reported that elevation of AEA concentrations in the striatum by FAAH inhibition or depletion reduced the levels, metabolism, and physiological effects of 2-AG. It is possible that elevated striatal AEA has modulatory effects on metabolism of NADA, thereby reducing its levels in the striatum, and future studies will address this issue.
Early studies showed that AEA can be synthesized by conjugation of arachidonic acid and ethanolamine and this reaction might be catalyzed by FAAH acting in reverse [29, 30] . However, this pathway was later shown to be unlikely given that AEA is an excellent substrate for FAAH (also confirmed here); thus the rate of AEA hydrolysis by FAAH was much greater than AEA synthesis from the conjugation of arachidonic acid and ethanolamine. Later research found that there are at least three potential pathways involved in AEA biosynthesis that includes several novel enzymes such as N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD), glycerophosphodiesterase (GDE1), a/b hydrolase 4 (ABHD4), or an unknown phosphatase [31] [32] [33] [34] [35] . To date, there are no known N-acyl phosphatidyldopamines, so these analogous pathways are highly unlikely.
The possibility that FAAH is a candidate for an enzyme complex involved in NADA biosynthesis is in further agreement with the observation that NADA is a poor substrate for FAAH [1] . We confirmed this observation here and showed that the rate of hydrolysis of NADA by FAAH is dramatically lower than that of AEA (7-fold at 3 min and 5-fold at 30 min). When AEA was incubated with FAAH in the presence of dopamine, NADA was synthesized in trace amounts. Our HPLC/MS/MS method for detection of NADA is $500 atamoles and, therefore, the most sensitive published to date. In fact, previous methods used in this study for our earlier assays would not have detected these trace amounts. The largest amount of production of NADA ($3%) was at 30 min when there were only trace amounts of AEA left in the solution, so that the substrates available were arachidonic acid and dopamine. Given that FAAH is an integral membrane protein and that recombinant FAAH is in an unbound state in vitro, it is unlikely to act in exactly the same manner as the bound state in vivo. It is difficult to determine whether the synthesis of NADA in vitro represents the result of an energetically favorable reaction or the result of FAAH acting as a biosynthetic enzyme at a suboptimal level given that its conformation is potentially different from that in the membrane-bound form. Future studies will address this issue.
In conclusion, we report here in vitro and in vivo evidence that NADA biosynthesis in rat brain depends on TH in dopaminergic terminals and that this endocannabinoid/endovanilloid can be made from the conjugation of dopamine with arachidonic acid, but that it is likely not formed via NA-tyrosine and NA-L-DOPA intermediates. Our data suggest a direct involvement of FAAH in NADA biosynthesis either as a rate-limiting enzyme that liberates arachidonic acid from AEA, or as a conjugation enzyme, or both. Further investigations are needed to elucidate the exact molecular details of this enzymatic process.
